Skip to Main content Skip to Navigation
Journal articles

Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases

Abstract : Local or national policy, patients' preferences, safety and/or economic concerns, or reimbursement issues may dictate stopping drug in inflammatory bowel diseases (IBD) patients. Sustained deep remission is an important predictor of a better outcome after anti-tumor necrosis (TNF) factor therapy discontinuation, including infliximab (IFX) in IBD patients, but this is not sufficient to prevent future relapse in these patients. In IBD patients under combotherapy, trough level of infliximab (TRI) could be helpful to choose stopping one of the two drugs. In patients on IFX monotherapy, TRI could help to decide reduction of drug dosing, particularly in IBD patients with supratherapeutic trough levels. Incidental findings of undetectable TRI in patients with deep remission may identify a subset of patients who may be considered for IFX cessation. Controlled trials further assessing this issue are eagerly awaited. Pending these trials, clear international recommendations for discontinuing anti-TNF therapy are needed.
Document type :
Journal articles
Complete list of metadata
Contributor : Ngere Ul Connect in order to contact the contributor
Submitted on : Friday, January 12, 2018 - 3:39:27 PM
Last modification on : Tuesday, October 13, 2020 - 10:46:50 AM




Nicolas Williet, Stéphane Paul, Laurent Peyrin-Biroulet, Xavier Roblin. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases. Digestive Diseases and Sciences, Springer Verlag, 2016, 61 (4), pp.990 - 995. ⟨10.1007/s10620-015-3984-2⟩. ⟨hal-01682890⟩



Record views